ArticlePloS one2014
A genetic variant in the promoter region of miR-106b-25 cluster predict clinical outcome of HBV-related hepatocellular carcinoma in Chinese.
Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 24 citations in OpenAlex.
- MicroRNA polymorphism: A target for diagnosis and prognosis of hepatocellular carcinoma?Oncology letters · 2021Review
- The AutGO Initiative: A Conceptual Framework for Developing Genetics-Outcomes Research Hypotheses.Autism research : official journal of the International Society for Autism Research · 2020Article
- IL-6 promotes PD-L1 expression in monocytes and macrophages by decreasing protein tyrosine phosphatase receptor type O expression in human hepatocellular carcinoma.Journal for immunotherapy of cancer · 2020Article
- Modelling the Effects of MCM7 Variants, Somatic Mutations, and Clinical Features on Acute Myeloid Leukemia Susceptibility and Prognosis.Journal of clinical medicine · 2020Article
- MCMs in Cancer: Prognostic Potential and Mechanisms.Analytical cellular pathology (Amsterdam) · 2020Review
- Incorporating MicroRNA into Molecular Phenotypes of Circulating Tumor Cells Enhances the Prognostic Accuracy for Patients with Metastatic Breast Cancer.The oncologist · 2019Article
- A genetic variant rs13293512 in the promoter of let-7 is associated with an increased risk of breast cancer in Chinese women.Bioscience reports · 2019Article
- Identification of potential miRNA-mRNA regulatory network contributing to pathogenesis of HBV-related HCC.Journal of translational medicine · 2019Article
- Multivariate analysis of clinicopathological and prognostic significance of miRNA 106b~25 cluster in gastric cancer.Cancer cell international · 2019Article
- Single Nucleotide Polymorphisms inBioMed research international · 2018Article
- MiRNA Polymorphisms and Cancer Prognosis: A Systematic Review and Meta-Analysis.Frontiers in oncology · 2018Article
- MicroRNA-Related Polymorphisms in Infectious Diseases-Tiny Changes With a Huge Impact on Viral Infections and Potential Clinical Applications.Frontiers in immunology · 2018Review
- A polymorphism rs4705341 in the flanking region of miR-143/145 predicts risk and prognosis of colorectal cancer.Oncotarget · 2016Article
- MicroRNAs as possible biomarkers for diagnosis and prognosis of hepatitis B- and C-related-hepatocellular-carcinoma.World journal of gastroenterology · 2016Review
- A genetic variant in large tumor suppressor kinase 2 of Hippo signaling pathway contributes to prognosis of hepatocellular carcinoma.OncoTargets and therapy · 2016Article
- Noncoding RNA as therapeutic targets for hepatocellular carcinoma.Seminars in liver disease · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMiR-106b-25 cluster, hosted in intron 13 of MCM7, may play integral roles in diverse processes including immune response, tumorigenesis and progression. A single nucleotide polymorphism (SNP), rs999885, is located in the promoter region of MCM7. Our previous study showed that the A to G base change of rs999885 may provide an increased risk for HCC in HBV persistent carriers by altering the expression of the miR-106b-25 cluster. However, it is unknown whether rs999885 is associated with prognosis of intermediate or advanced HBV-related hepatocellular carcinoma (HCC) patients.
methodsThe SNP, rs999885, was genotyped by using the TaqMan allelic discrimination Assay in 414 intermediate or advanced HCC patients. Log-rank test and Cox proportional hazard models were used for survival analysis.
resultsThe variant genotypes of rs999885 were associated with a significantly decreased risk of death for intermediate or advanced HCC [additive model: adjusted hazard ratio (HR) = 0.76,95% confidence intervals (CI) = 0.59-0.97]. Further stepwise regression analysis suggested that rs999885 was an independently protective factor for the prognosis of HCC in the final model (additive model: adjusted HR = 0.72, 95% CI = 0.56-0.91, P = 0.007).
conclusionsThese findings indicate that the A to G base change of rs999885 may provide a protective effect on the prognosis of intermediate or advanced HCC in Chinese.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.